Adverse reactions in clinical trials occurring at an incidence of ≥2% and more commonly than placebo in the RHINOCORT® group in patients 6 years and older*
A similar adverse event profile was observed in the subgroup of pediatric patients 6-12 years of age. These patients are included in the table. Two to three percent (2%-3%) of patients in the clinical trials discontinued because of adverse reactions.
2%-3% of patients in clinical trials discontinued due to adverse reactions